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Abstract
Introduction. Special entities like solitary bone plasmocy-
toma (SBP) or extramedullary plasmacytoma (EMP) can be
found in a less than 5% of patients with plasma cell disorders.
EMP of the tongue represents very rare localization of the
head and neck plasmacytoma. Case report. We report a case
of 78-years-old woman who developed EMP of the tongue
base detected by the magnetic resonance imaging (MRI) of
the head and neck region. Immunohistochemical profile of
the tumor tissue biopsy (CD38, IgG, kappa positivity) indi-
cated diagnosis of EMP. The diagnosis was established with
additional staging which confirmed the absence of other
manifestation of the disease. The patient was treated with 40
Gy of radiotherapy in 20 doses resulting in the achievement
of the complete remission of the disease. This case was dis-
cussed with the reference to the literature. Conclusion. EMP
of the tongue base is a very rare entity of plasma cell dyscra-
sias. Appropriate irradiation results in the achievement of a
long-term remission and a potential cure of the disease.
Key words:
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Apstrakt
Uvod. Posebni entiteti kao što su solitarni plazmocitom
kostiju ili ekstramedularni plazmocitom (EMP) mogu se
naýi kod manje od 5% bolesnika sa plazmaýelijskim obo-
ljenjima. Ekstramodularni plazmocitom baze jezika je ve-
oma retka lokalizacija plazmocitoma glave i vrata. Prikaz
bolesnika. U radu je prikazana bolesnica, stara 78 godina,
sa EMP baze jezika, ÿije postojanje je ustanovljeno mag-
netnom rezonancom (MR) glave i vrata. Imunohistohemij-
skim profilom bioptata tumorskog tkiva (CD38, IgG, kap-
pa pozitivnost) potvrĀena je dijagnoza EMP. Dopunskim
ispitivanjima ustanovljeno je odsustvo drugih manifestacija
bolesti. Bolesnica je leÿena lokalnom zraÿnom terapijom sa
40 Gy u 20 seansi, ÿime je postignuta kompletna remisija
bolesti.  Zakljuÿak. Ekstramodularni plazmocitom baze
jezika je veoma redak vid ispoljavanja plazmaýelijskih
oboljenja. Odgovarajuýom zraÿnom terapijom postižu se
dugotrajne remisije bolesti uz postojanje potencijalne mo-
guýnosti izleÿenja.
Kljuÿne reÿi:
plazmocitom; dijagnoza; jezik; radioterapija; leÿenje,
ishod.
Introduction
Plasmacytomas are localized tumors consisting of
monoclonal plasma cells that may develop in either bones or
soft tissue 
1. Less than 5% of patients with plasma cell dys-
crasia present with a single bone or extramedullary lesion
due to a malignant plasma cell infiltrate, without apparent
evidence of systemic myeloma. Solitary extramedullary
plasmacytoma (EMP) is less common than solitary bone
plasmacytoma (SBP) and occurs when there is soft tissue in-
filtration of clonal plasma cells. EMP is approximately three
times more often in men than in women, usually in the age
group of 50–70 years. The diagnosis requires biopsy confir-
mation of monoclonal plasma cells from single site. There
should be no evidence of bone destruction, clonal marrow
plasmacytosis or occult disease elsewhere 
2. Approximately
85% of lesions occur in the head and neck mucosa probably
related to long-term stimulation by inhaled irritants or viral
infection. An underlying bone involvement, particularly in
the sinuses, may be noted. They account for fewer than 1%
of all head and neck tumors 
3. Gastrointestinal involvement,
although significantly less common, is the next most fre-
quent site, and other areas of involvement, reported infre-
quently, include: lung, bladder, thyroid, testis, ovary, andVolumen 70, Broj 10 VOJNOSANITETSKI PREGLED Strana 973
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tonsil among other. Solitary plasmacytomas of the tongue
base are rare tumors that occurre in 1.7% of all EMPs in the
upper aerodigestive tract 
4, 5. Similar to the SBP, EMPs are
highly radiosensitive with nearly all patients successfully
achieving local control and approximately 50–65% of pa-
tients remaining free of disease longer than 10 years. Due to
small patient numbers and historical retrospective analyses
over many decades, no firmly established treatment criteria
exist 
6, 7.
Its rare occurance and variety of clinical manifestations
may cause clinical uncertainty prior to the receipt a histo-
logic and hematologic diagnosis. With an idea to highlight
diagnosis and treatment modalities, in this presentation we
report a case of extramedullary plasmacytoma of the tongue
base.
Case report
In July 2010, a 78-year-old woman was admitted with
complaints as tongue swelling without any other symptoms.
The patient past medical history revealed durable five years
of complete remission after surgical removal of the colorec-
tal carcinoma.
Physical exam showed an elastic, irregular tumor mass
at the ventral left side of the tongue base without significant
lymphadenopathy. The magnetic resonance imaging (MRI)
exam of the head and neck region confirmed tumor mass of
3.5 u 2.5 u 1.0 cm size at the ventral left side of the tongue
(Figure 1).
Tumor biopsy showed massive diffuse infiltrate of ab-
normal plasma cells (70%) with the following immunohisto-
chemical profile (Figure 2): CD38+++ (70% cells); kappa ++
(30% cells); lambda- (< 10% cells); IgG++ (60% cells);
p53+ (20% cells); FGFR3- (< 10% cells). Blood count was
normal (Hb 123 g/L, WBC 6.0 u 10
9/L, PLT 170 u 10
9/L).
Results of the other laboratory tests were unremarkable
with normal levels of the erythrocyte sedimentation rate (14),
total proteins (80 g/L), without renal impairment and pro-
teinuria (0.08g/24h), and without suppression of the unin-
volved immunoglobulins. Protein electrophoresis with im-
munofixation did not confirm the existence of monoclonal
(M) protein accompanied with the absence of Bence Jones
proteinuria. Bone marrow (BM) trephine biopsy with immu-
nohistochemical staining did not show plasma cell infiltra-
tion accompanied with positive expression of osteoprotegerin
(OPG, 25% cells) and the absence of receptor activator of
nuclear factor țB ligand (RANKL, < 10% cells). An x-ray
skeletal survey found no osteolytic or neoplastic processes
followed with normal MRI of the axial skeleton. Computed
tomography (CT) scan of the chest and abdomen did not re-
veal any pathological findings. The patient was negative for
the tumor (CEA, CA19.9, CA125) and viral (HBsAg, HCV,
HIV, HHV8) markers.
Following above mentioned exams, the diagnosis of
solitary EMP of the tongue base was established. The patient
was treated with 40 Gy of a local radiotherapy in 20 doses
achieving complete remission confirmed at the last control
check-up in December 2010.
Discussion
In comparison to SBP, solitary EMP is less common
than SBP. Solitary plasmacytoma of the tongue is extremely
rare, with only a few cases having been reported in the Eng-
lish literature 
8–14. This entity requires distinction from reactive
plasmacytosis, plasma cell granuloma and lymphoproliferative
disorders like mucosa-associated lymphoid tissue (MALT),
marginal zone, and immunoblastic lymphoma 
3, 15, 16. It is sus-
pected that in pathogenesis of EMP, both of clonal event
(chromosomal abnormalities, i.e. losses at 13q) and IL-6 are
required 
1. In accordance with literature data, our patient is
the senior female who developed EMP of the tongue base in
the age of 78 years 
2. The immunohistochemical profile of
the tumor in our patient indicated massive diffuse infiltration
Fig. 1 – Magnetic resonance imaging (MRI) findings of the head and neck region showing tumor mass on the ventral left side
of the tongue base.Strana 974 VOJNOSANITETSKI PREGLED Volumen 70, Broj 10
 Bila J, et al. Vojnosanit Pregl 2013; 70(10): 972–975.
with monoclonal CD38 and IgG kappa positive plasma cells.
Phenotypic studies for CD38 and monoclonal cytoplasmic
light chain expression of malignant plasma cells obtained by
biopsy or fine needle aspiration of the solitary lesion are nec-
essary for the accomplishment of the EMP diagnosis 
2, 15, 16.
Aberrant expression of fibroblast growth receptor 3 onco-
gene (FGFR 3) as a product of t (4,14) is present in approxi-
mately 15% of myeloma patients and contribute to myeloma
progression. Lack of  FGFR 3 expression in our patient could
explain the indolent course of disease 
17. The absence of
bone disease in the patient concurs with the findings of both
low expression of RANKL in the bone marrow as a marker
of octeoclastic activity and pronounced expression of its
naturally occurring decoy receptor, OPG 
18. Additionally, ac-
cording to the literature data 
1, the lack  of CD56 expression
could indicate the lack of bone disease in EMP. Confirma-
tion of the diagnosis requires as well the absence of bone
marrow infiltration, skeletal events or any signs of sympto-
matic disease elsewhere 
1–3, 15, 16.
In order to verify the extent of the solitary lesion, CT or
MRI is required. Similarly to SBP and 1A clinical stage of
myeloma, spinal MRI was performed in the patient for the
accurate staging of EMP indicating the absence of the bone
disease. Although there was no detectable M-protein in the
serum and urine of our patient, by electrophoresis and im-
munofixation its low levels can be detected in less than 25%
of patients with EMP or SBP 
2, 3, 15, 16. Additionally, normal
level of uninvolved immunoglobulin in the patient confirmed
the absence of occult disease elsewhere. Serum-free light
chain assays could be useful in staging EMP and SBP pa-
tients, accompanied with the absence of underlying myeloma
by bone survey and abnormalities of biochemistry attached
to plasma cell disorders 
19.
Due to a small number of patients, there are no estab-
lished criteria for the treatment. Both entities, SBP and EMP,
are highly radiosensitive. The achievement of local control is
expected in nearly all patients. About half of these will re-
main free of the disease longer than 10 years. In accordance
with the literature, elective radiotherapy with 40 Gy of mean
irradiation dosage  was applied in the described patient 
4, 7 re-
sulting in the achievement of a complete remission after irra-
diation at the last three months of follow-up. The United
Kingdom Myeloma Forum recommended radiotherapy dose
of 40 Gy in 20 fractions for tumors < 5 cm and up to 50 Gy
in 25 fractions for tumors a 5 cm with at least a 2 cm margin
encompassing the primary tumor. Involvement of cervical
nodes or Waldeyer’s ring tumors requires inclusion in the ra-
diotherapy field 
16. Radical surgery of the head and neck is a
generally mutilating procedure that is not indicated as the
tumours are generally highly radiosensitive and the majority
CD38+ CD138+
IgG+ kappa+
Fig. 2 – Immunohistochemical profile of the tumor tissue biopsy (CD38+, CD138+, IgG+, kappa +).Volumen 70, Broj 10 VOJNOSANITETSKI PREGLED Strana 975
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of patients are cured with radiotherapy. Nevertheless, sur-
gery may be considered for other sites of disease, such as the
gastrointestinal tract 
20. Comparing patients with sites other
than the head and neck, who received either surgery, radia-
tion, or a combined-modality treatment, there was no differ-
ence among these 3 arms, suggesting that either surgery or
radiotherapy is reasonable for such patients. At the present
time, adjuvant chemotherapy is not indicated because it has
not been shown to reduce relapse or improve survival rates.
However, it can be used at the time of recurrence or dissemi-
nation of the disease 
2, 16, 19–21.
Less than 10% of patients have local reccurence of the
disease, with achievement of 50–80% of the 10-year disease
free and overall survival in 30–50% of patients who develop
disease progression to myeloma. The progression to mye-
loma might occur after the median of 1.5–2.5 years. The
clinical course at progression of these patients is similar to
patients with newly diagnosed symptomatic myeloma. Pos-
sible risk factors for EMP evolution to myeloma may be
bulky disease > 5 cm, elderly age, suppression of uninvolved
immunoglobulins and persisting M protein for more than one
year after radiotherapy indicating age as the only one posi-
tive risk factor in our patient 
2, 7, 16.
Conclusion
EMP of the tongue base is a very rare entity of plasma
cell dyscrasias accounting less than 1% of all head and neck
tumors. Appropriate irradiation results in a log-term stability
and potential cure in more than half of the patients. Spinal
MRI and new modalities of the disease monitoring like se-
rum free-light chain assay might be of significance for stag-
ing and risk stratification. More detailed individual patient
data analyses of the hitherto published cases are needed to
identify different prognostic subgroups of patients and opti-
mal treatment approach.
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